Want to see PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
$1.43
$0.01(0.70%)
At close: 4:00 PM EDT
$1.43
$0.01(0.70%)
Day’s Range― - ―
52-Week Range$1.16 - $24.00
Previous Close$1.45
Volume11.51K
Average Volume (3M)415.61K
Market Cap
$10.97M
Enterprise Value-$4.20
Total Cash (Recent Filing)$6.11M
Total Debt (Recent Filing)$134.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 13, 2026EPS Estimate
-2.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9849.94
Shares Outstanding1,620,861
10 Day Avg. Volume296,099
30 Day Avg. Volume415,608
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.00Price Target Upside1088.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated CAPTN-3 Immuno-oncology PlatformThe masked tri-specific design addresses major limitations of existing T-cell engagers in solid tumors. Dual immune-cell engagement and tumor-selective activation could support durable competitive differentiation if clinical testing confirms the preclinical safety and efficacy profile.
Promising Preclinical Efficacy And Safety DataConsistent efficacy across patient-derived resistant tumor models, combined with improved pharmacokinetics and limited cytokine release, strengthens the scientific rationale for clinical development. These findings may improve partnering prospects and reduce safety-related development risk.
Low Leverage Reduces Refinancing RiskMinimal debt limits interest, covenant, and refinancing pressure while the company advances its pipeline. Although the balance sheet is constrained by losses, low leverage gives management greater flexibility to use equity, partnerships, or other funding without servicing a significant debt burden.
Bears Say
No Established Revenue Base And Widening LossesThe absence of recurring commercial revenue leaves valuation support and operating funding dependent on future milestones, partnerships, or financing. Continued losses show that the pipeline has not yet created a stable economic engine and could increase dilution risk.
Persistent Cash Burn And Limited Funding RunwayNegative cash generation means the company remains dependent on external capital before clinical assets can produce revenue. The stated runway is defined but limited, creating recurring financing risk as Phase 1 development and other pipeline work require additional resources.
Clinical-stage Execution And Partnership DependenceThe lead program remains preclinical, so the key claims about safety and efficacy have not yet been validated in humans. Delays, unfavorable clinical results, or failure to secure partners could materially reduce pipeline value and prolong the company’s unprofitable funding cycle.
Purple Biotech News
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $1.16 and its highest was $24.00 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is $10.97M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Nov 13, 2026 which is in 87 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Aug 07, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of $0.35 by -$0.76.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -2.88.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,620,861 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.41 in its last earnings report, missing expectations of $0.35. Following the earnings report the stock price went up 1.418%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
PPBT Stock 12 Month Forecast
Average Price Target
$17.00
▲(1088.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.76% Other Institutional Investors
98.24% Public Companies and
Individual Investors